Clinical Trial Update: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of tafasitamab, lenalidomide and venetoclax for relapsed or refractory mantle cell lymphoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)
• Venclexa (venetoclax)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING